Alcyone Therapeutics
Alcyone Therapeutics was a clinical-stage biotech developing AAV gene therapies and the ThecaFlex DRx intrathecal drug delivery platform for rare pediatric neurological diseases, acquired by Biogen for $85 million in November 2025.
- Company typePrivate
- Founded2021
- HeadquartersLowell, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alcyone Therapeutics does
Alcyone Therapeutics was a clinical-stage biotechnology company founded in June 2021 and headquartered in Lowell, Massachusetts, focused on developing next-generation precision genetic therapies for rare pediatric neurological diseases of the central nervous system (CNS). The company operated with 11-50 employees and was built around a proprietary CNS Precision Delivery Platform combined with a pipeline of 12 AAV (adeno-associated virus) gene therapy programs targeting indications including CLN3 Batten disease and Rett syndrome. Its lead clinical asset, CLN-301, was an experimental AAV gene therapy for CLN3 Batten disease in Phase 1/2 trials with early promising safety and efficacy data.
The company's most differentiated technology was ThecaFlex DRx, an investigational implantable port-and-catheter intrathecal (IT) drug delivery system that received FDA Breakthrough Device designation. ThecaFlex DRx is designed to provide long-term repeated IT access following a single surgical implantation, eliminating the risks and burden associated with repeated lumbar punctures for delivering antisense oligonucleotides and other CNS therapies. Alcyone advanced these programs through a strategic collaboration with Nationwide Children's Hospital and the Abigail Wexner Research Institute, which provided both research infrastructure and a strategic financing round in April 2025.
As a pre-commercial clinical-stage biotech, Alcyone had no marketed products and its revenue model was structured around future licensing or product sales upon regulatory approval. The company was acquired by Biogen Inc. for approximately $85 million in a deal announced September 2025 and completed November 2025, with the strategic rationale centered on ThecaFlex DRx as a drug-device combination platform applicable to Biogen's existing antisense oligonucleotide franchise, including SPINRAZA for spinal muscular atrophy.
Alcyone Therapeutics firmographics
Firmographics- Name
- Alcyone Therapeutics
- Legal name
- Alcyone Therapeutics
- Website
- https://alcyonetx.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Alcyone Therapeutics was a clinical-stage biotech developing AAV gene therapies and the ThecaFlex DRx intrathecal drug delivery platform for rare pediatric neurological diseases, acquired by Biogen for $85 million in November 2025.
- Ownership category
- akta.pro rank
Alcyone Therapeutics industry classification
Industry- Product category
- CNS Gene Therapy and Drug Delivery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Neurology/CNS Gene Therapies (HLAAACAH), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Alcyone Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lowell
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alcyone Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Gene Therapy Development: Pre-commercial clinical-stage biotech developing gene therapies for rare pediatric neurological diseases. Revenue generation model would involve pharmaceutical licensing or product sales upon regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Alcyone Therapeutics product offering
Product offeringCore offering
Alcyone Therapeutics is a clinical-stage biotechnology company developing next-generation gene therapies and precision drug delivery platforms for central nervous system (CNS) disorders. Its core offerings include the ThecaFlex DRx implantable intrathecal delivery system and a pipeline of AAV gene therapy programs targeting rare pediatric neurological diseases such as CLN3 Batten disease and Rett syndrome. The company's proprietary CNS Precision Delivery Platform underpins both the gene therapy pipeline and the ThecaFlex DRx medical device, which together aim to improve safety, efficacy, and treatment burden for CNS genetic medicines.
Product overview
Alcyone Therapeutics was a clinical-stage biotech company developing next-generation gene therapies for CNS disorders using proprietary CNS precision delivery platforms. The company's core products included CLN-301, an AAV gene therapy for CLN3 Batten disease in Phase 1/2 trials, and ThecaFlex DRx, an implantable intrathecal drug delivery system. The pipeline comprised 12 AAV gene therapy programs targeting rare pediatric neurological diseases. The company was acquired by Biogen in November 2025 for approximately $85 million, with ThecaFlex DRx being developed to improve CNS therapy delivery, particularly for SPINRAZA.
Differentiator
Problem solved
Functional benefit
Brands
- ThecaFlex DRx: An investigational implantable device for intrathecal drug delivery, designed to provide long-term repeated IT access following a single surgical implantation, eliminating the need for repeat lumbar punctures.
Products and services
- ThecaFlex DRx System An investigational implantable port-and-catheter intrathecal (IT) drug delivery system designed to provide long-term repeated IT access following a single surgical implantation, eliminating the need for repeat lumbar punctures. It is intended for delivery of antisense oligonucleotides and other CNS therapies, particularly SPINRAZA for spinal muscular atrophy patients.
- CLN-301 Gene Therapy An experimental AAV gene therapy candidate for CLN3 Batten disease, a rare pediatric neurological disorder. Currently in Phase 1/2 clinical trials with early results showing promising safety and efficacy as a potential first-in-class treatment.
- AAV Gene Therapy Programs (Pipeline) A pipeline of 12 AAV (adeno-associated virus) gene therapy programs targeting pediatric neurological diseases including Rett syndrome and CLN3 Batten disease, developed using proprietary CNS delivery platforms and multiple gene therapy technologies.
Quantifiable outcome
- CLN-301 showed promising safety and efficacy in early Phase 1/2 trials
- +1 more outcomes
Companies that use Alcyone Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Alcyone Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alcyone Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- BiogenflagshipBiogen acquired Alcyone Therapeutics for $85 million in September 2025, with completion in November 2025. The acquisition focused on ThecaFlex DRx, an investigational implantable device for intrathecal delivery of antisense oligonucleotides, to enhance Biogen's capabilities in drug-device combination products for neurological disorders.
- Nationwide Children's HospitalcoreStrategic financing and expanded collaboration with Nationwide Children's Hospital to develop pediatric neurological disease treatments including CLN-301 gene therapy for CLN3 Batten disease. Collaboration includes clinical and research development with the Abigail Wexner Research Institute.
Scale indicators4 records
Recent moves4 records
Expansion highlights4 records
Alcyone Therapeutics competitors and assessment
Company assessmentDirect peers
- Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for severe neurological diseases, with a focus on CNS delivery and rare neurological indications — directly comparable to Alcyone's CNS precision delivery approach and AAV pipeline.
- Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based treatments for rare monogenic neurological diseases of the CNS, with a broad pipeline — closely comparable to Alcyone's pediatric CNS AAV pipeline targeting conditions like Rett syndrome.
- Passage Bio: Clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases — directly comparable to Alcyone's CNS AAV pipeline and rare pediatric neurology focus.
- Lexeo Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for genetic CNS and cardiac diseases — comparable to Alcyone in CNS AAV delivery and rare disease focus.
- uniQure: Clinical-stage AAV gene therapy company with CNS programs (e.g., Huntington's disease) using proprietary AAV delivery technology — directly comparable to Alcyone's CNS delivery and AAV platform approach.
- Regenxbio: Gene therapy company developing AAV vectors and a broad pipeline including CNS and neuromuscular programs — comparable as an AAV platform peer to Alcyone's AAV pipeline and delivery technology.
Broad incumbents
- Sarepta Therapeutics: Established commercial-stage gene therapy and RNA-based therapeutics company with approved products for rare neuromuscular diseases (e.g., DMD, SMA-adjacent) — broader incumbent competing with Alcyone in CNS/neuromuscular gene therapy space.
- Ionis Pharmaceuticals: Antisense oligonucleotide (ASO) leader partnered with Biogen on SMA (SPINRAZA) — directly comparable as a CNS ASO/drug-device combination peer and a critical Biogen collaborator for ThecaFlex DRx.
- Novartis (Zolgensma / gene therapy unit): Markets Zolgensma, an AAV9 gene therapy for SMA — directly comparable incumbent in the SMA gene therapy space and adjacent to Alcyone's CNS AAV pipeline.
- BioMarin Pharmaceutical: Established gene therapy company with approved AAV product (Roctavian) and broader rare-disease pipeline — comparable as an established AAV gene therapy incumbent with device/drug combination complexity.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Alcyone Therapeutics social profiles
Digital presenceAlcyone Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alcyone Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Alcyone Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alcyone Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alcyone Therapeutics
What does Alcyone Therapeutics do?
Alcyone Therapeutics is a clinical-stage biotechnology company developing next-generation gene therapies and precision drug delivery platforms for central nervous system (CNS) disorders. Its core offerings include the ThecaFlex DRx implantable intrathecal delivery system and a pipeline of AAV gene therapy programs targeting rare pediatric neurological diseases such as CLN3 Batten disease and Rett syndrome. The company's proprietary CNS Precision Delivery Platform underpins both the gene therapy pipeline and the ThecaFlex DRx medical device, which together aim to improve safety, efficacy, and treatment burden for CNS genetic medicines.
Is Alcyone Therapeutics a public or private company?
Alcyone Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Alcyone Therapeutics founded?
Alcyone Therapeutics was founded in 2021. It employs 11 to 50 people.
Where is Alcyone Therapeutics based?
Alcyone Therapeutics is headquartered in Lowell, United States, in the North America region.
How does Alcyone Therapeutics make money?
One revenue line is on record: gene Therapy Development.
Who are Alcyone Therapeutics's main competitors?
Direct peers on record are Voyager Therapeutics, Taysha Gene Therapies, Passage Bio, Lexeo Therapeutics, uniQure and Regenxbio. Broad incumbents are Sarepta Therapeutics, Ionis Pharmaceuticals, Novartis (Zolgensma / gene therapy unit) and BioMarin Pharmaceutical.
Does Alcyone Therapeutics have an API?
No public API is recorded for Alcyone Therapeutics.
What industry is Alcyone Therapeutics in?
Alcyone Therapeutics's product category is CNS Gene Therapy and Drug Delivery. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its NAICS code is 541714 and its SIC code is 2836.